il 17a neutralizing affibody molecule Search Results


il 17a affibody molecule  (Affibody)
86
Affibody il 17a affibody molecule
<t>IL-17A/F</t> signaling pathway and targeted therapeutics. IL-17 binds to the IL-17RA/RC receptor complex, which exists as a heterodimer on target cells. Upon ligand binding, the adaptor protein Act1 is recruited to the receptor via SEFIR domain interactions, leading to the formation of an Act1–TRAF6 complex. This complex activates downstream signaling cascades, including the NF-κB pathway via TAK1–IKK complex formation and the MAPK pathways via ERK, p38, and JNK. Meanwhile, IL-17 signaling can directly activate C/EBPβ via the CBAD, further enhancing transcriptional responses. The signaling pathways activate gene transcription, which produces pro-inflammatory mediators and antimicrobial peptides. TRAF2/5 protects mRNA from degradation, while TRAF3 serves as a critical negative regulator of IL-17 signaling. Secukinumab, Ixekizumab, Brodalumab, and Bimekizumab are biologic agents targeting IL-17 isoforms and IL-17 receptor subunits for treatment purposes; Sonelokimab and Izokibep represent experimental drugs not received approval for medical applications. MAPK: mitogen-activated protein kinase; NF-κB: nuclear factor-κB; C/EBPβ: CCAAT/enhancer-binding protein β; CBAD: C/EBPβ activation domain.
Il 17a Affibody Molecule, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+17a+neutralizing+affibody+molecule/17a+affibody+il+molecule+neutralizing/pmc13024237-21-2-3
Average 86 stars, based on 1 article reviews
il 17a affibody molecule - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


IL-17A/F signaling pathway and targeted therapeutics. IL-17 binds to the IL-17RA/RC receptor complex, which exists as a heterodimer on target cells. Upon ligand binding, the adaptor protein Act1 is recruited to the receptor via SEFIR domain interactions, leading to the formation of an Act1–TRAF6 complex. This complex activates downstream signaling cascades, including the NF-κB pathway via TAK1–IKK complex formation and the MAPK pathways via ERK, p38, and JNK. Meanwhile, IL-17 signaling can directly activate C/EBPβ via the CBAD, further enhancing transcriptional responses. The signaling pathways activate gene transcription, which produces pro-inflammatory mediators and antimicrobial peptides. TRAF2/5 protects mRNA from degradation, while TRAF3 serves as a critical negative regulator of IL-17 signaling. Secukinumab, Ixekizumab, Brodalumab, and Bimekizumab are biologic agents targeting IL-17 isoforms and IL-17 receptor subunits for treatment purposes; Sonelokimab and Izokibep represent experimental drugs not received approval for medical applications. MAPK: mitogen-activated protein kinase; NF-κB: nuclear factor-κB; C/EBPβ: CCAAT/enhancer-binding protein β; CBAD: C/EBPβ activation domain.

Journal: Biomolecules

Article Title: The Double-Edged Sword of Type 17 Immunity in Wound Healing and Skin Barrier Repair: Microenvironment-Driven Functional Plasticity

doi: 10.3390/biom16030414

Figure Lengend Snippet: IL-17A/F signaling pathway and targeted therapeutics. IL-17 binds to the IL-17RA/RC receptor complex, which exists as a heterodimer on target cells. Upon ligand binding, the adaptor protein Act1 is recruited to the receptor via SEFIR domain interactions, leading to the formation of an Act1–TRAF6 complex. This complex activates downstream signaling cascades, including the NF-κB pathway via TAK1–IKK complex formation and the MAPK pathways via ERK, p38, and JNK. Meanwhile, IL-17 signaling can directly activate C/EBPβ via the CBAD, further enhancing transcriptional responses. The signaling pathways activate gene transcription, which produces pro-inflammatory mediators and antimicrobial peptides. TRAF2/5 protects mRNA from degradation, while TRAF3 serves as a critical negative regulator of IL-17 signaling. Secukinumab, Ixekizumab, Brodalumab, and Bimekizumab are biologic agents targeting IL-17 isoforms and IL-17 receptor subunits for treatment purposes; Sonelokimab and Izokibep represent experimental drugs not received approval for medical applications. MAPK: mitogen-activated protein kinase; NF-κB: nuclear factor-κB; C/EBPβ: CCAAT/enhancer-binding protein β; CBAD: C/EBPβ activation domain.

Article Snippet: Izokibep , IL-17A affibody molecule , HS, PsA , Phase III.

Techniques: Ligand Binding Assay, Protein-Protein interactions, Binding Assay, Activation Assay